Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 14/20 | 0.68 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.64 |
| ▸ | PTGES | O14684 | 1/20 | 0.64 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.62 |
| ▸ | CNR2 | P34972 | 1/20 | 0.62 |
| ▸ | APLNR | P35414 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7365048 | 0.85 | TAS2R14 (0.68) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL1888996 | 0.85 | TAS2R14 (0.81) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL22501451 | 0.85 | TAS2R14 (0.68) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL2109904 | 0.85 | TAS2R14 (0.68) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL2445958 | 0.84 | TAS2R14 (0.82) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL28729777 | 0.84 | TAS2R14 (0.80) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL24724004 | 0.81 | TAS2R14 (0.80) | TAS2R14CXCR3PTGESTAS2R8 | |
| SCHEMBL1279372 | 0.81 | TAS2R14 (1.00) | TAS2R14CXCR3PTGESTAS2R8 | |
| SCHEMBL1278960 | 0.81 | TAS2R14 (1.00) | TAS2R14CXCR3PTGESTAS2R8 | |
| SCHEMBL12260289 | 0.81 | TAS2R14 (0.67) | TAS2R14CXCR3PTGESTAS2R8CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3642195-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | NOVARTIS AG (CH) | 2020-03-31 | — | — | US | disclosed |
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | NOVARTIS AG (CH) | 2020-03-31 | — | — | US | disclosed |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-24 | — | — | US | disclosed |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-24 | — | — | US | disclosed |
| WO-2018234978-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | KDM1A, KDM5A, KDM1B | TAS2R14 4537/4885CXCR3 2730/4885PTGES 3831/4885 |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | KDM1A, KDM5A, KDM1B | TAS2R14 4537/4885CXCR3 2730/4885PTGES 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.